The media has been full of news about sight restoration from stem cells. In trials, stem cells are healing the retinal layer (retinal pigment epithelium) that supports the nerve cells (photoreceptors) responsible for seeing light. Scientists, however, have not yet been able to replace damaged photoreceptor cells in humans, but a recent study offers hope […]
by Dan Roberts London Eye Hospital Pharma announced today that it has initiated U.S. discussions to gain clinical data for its iolAMD lens system. iolAMD is a novel intraocular lens (IOL) system designed to restore lost vision and provide an independent lifestyle for patients with dry AMD and related diseases. The technology behind the iolAMD lens […]
by Dan Roberts For several years, eye doctors have been debating the value of tinted intraocular lenses (IOLs) in eyes that have undergone cataract surgery. Those in favor of them argue that they reduce the retina’s exposure to potentially hazardous ultraviolet and blue light. The main argument against them is that they cause a decrease […]
by Dan Roberts Advanced Cell Technology, Inc. (now owned by Astellas) has been conducting promising safety trials for stem cell treatment of macular degeneration, but a six-month follow up has yielded even better news than expected. ACT announced that Phase 1/2 clinical data treatment of Stargardt’s macular degeneration (SMD) and dry age-related macular degeneration (AMD). Surprising even […]
Genentech has announced that the FDA has granted its submission for Priority Review of Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. If approved, Lucentis could be the first eye medicine available for diabetic retinopathy patients. Lucentis […]